Publications by authors named "S Raimbault"
Background: Medulloblastoma (MB) is one of the most prevalent embryonal malignant brain tumors. Current classification organizes these tumors into four molecular subgroups (WNT, SHH, Group 3, and Group 4 MB). Recently, a comprehensive classification has been established, identifying numerous subtypes, some of which exhibit a poor prognosis.
View Article and Find Full Text PDFArticle Synopsis
- In September 2023, France launched a national immunization campaign using nirsevimab, a monoclonal antibody targeting respiratory syncytial virus (RSV).
- A case-control study was conducted with 288 infants from 20 pediatric intensive care units (PICUs) to assess the effectiveness of nirsevimab against severe RSV bronchiolitis.
- The study found nirsevimab to have an effectiveness of 75.9% in the main analysis, with higher estimates of 80.6% and 80.4% in sensitivity analyses, confirming its efficacy observed in previous clinical trials.
Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition, and its diagnosis may be challenging. In particular, some cases show close similarities to sepsis (fever, organ failure, and high ferritin), but their treatment, while urgent, differ: prompt broad-spectrum antibiotherapy for sepsis and immunosuppressive treatment for HLH. We questioned whether monocyte human leucocyte antigen (mHLA)-DR could be a diagnostic marker for secondary HLH (sHLH).
View Article and Find Full Text PDFImportance: Innovative anticancer therapies for children, adolescents, and young adults are regularly prescribed outside their marketing authorization or through compassionate use programs. However, no clinical data of these prescriptions is systematically collected.
Objectives: To measure the feasibility of the collection of clinical safety and efficacy data of compassionate and off-label innovative anticancer therapies, with adequate pharmacovigilance declaration to inform further use and development of these medicines.
Objective: Central-line-associated bloodstream infections (CLABSIs) are associated with significant morbidity among pediatric oncology-hematology patients, and risk factors remain largely unknown in the setting of hospital at home (HAH). Children in HAH receive intensive treatment (eg, chemotherapy and parenteral nutrition), with frequent central-line handling; thus, they may be at higher risk for CLABSI.
Methods: We conducted a monocentric retrospective study of patients with a central line included in our HAH program from January 1 to December 31, 2016.